FreeTheAI

FDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

BullishHigh impact
TEVA$41.10 4.71%

The U.S. Food and Drug Administration approved Weltruza, a once-monthly subcutaneous injection from Teva Pharmaceutical Industries Limited (NYSE:TEVA) to treat adults with schizophrenia. The medication, which delivers a steady dose of olanzapine, offers an alternative to daily oral pills. Following the announcement, Teva shares rose over 6% to trade at 41.63 USD.

Daily oral medications for schizophrenia often lead to adherence issues, raising the risk of patient instability and relapse. Weltruza aims to address this challenge by providing sustained release through a proprietary copolymer technology called SteadyTeq, developed by Medincell. In clinical trials, patients using the injection showed significant reductions in illness severity and improvements in social functioning.

Teva plans to launch the drug in the United States in the coming weeks, targeting an estimated 2.1 million Americans diagnosed with schizophrenia. The injection will be available in three strengths matching standard daily oral doses, without requiring loading doses or post-injection monitoring. Additionally, European regulators accepted a marketing application for the treatment in May 2026, paving the way for potential international expansion.

Key points

  • U.S. regulators approved Teva's Weltruza, a once-monthly injectable treatment for schizophrenia.
  • The drug aims to resolve common adherence issues associated with daily oral medications.
  • Clinical trials demonstrated significant improvements in patient symptoms and social functioning.
  • Teva plans to launch the drug in the U.S. in the coming weeks and is seeking European approval.
  • Teva shares rose over 6% following the FDA approval announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is Weltruza and how does it work?

Weltruza is a once-monthly subcutaneous injection for adult schizophrenia patients. It uses a proprietary technology to deliver a steady dose of olanzapine, eliminating the need for daily oral pills.

When will Weltruza be available in the United States?

Teva Pharmaceutical Industries Limited plans to launch the medication in the U.S. in the coming weeks to help treat the estimated 2.1 million Americans diagnosed with schizophrenia.

Does Weltruza require any special patient monitoring?

No, patients receiving Weltruza do not require loading doses, oral supplements, or post-injection monitoring.